The success of Sildenafil initially sparked a boom for major pharmaceutical companies, however recent changes present a murky picture for shareholders. Generic alternatives are eating into profits, and ongoing legal battles add further risk to the landscape. While specific companies could still gain from related products, the overall trajectory sug